| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The primary target of AMP-PCP is the N-terminal domain of heat shock protein 90 (Hsp90), a molecular chaperone involved in the folding, activation, and stabilization of numerous client proteins including kinases, steroid hormone receptors, and transcription factors. AMP-PCP binds to the ATP-binding pocket of Hsp90 with a Kd of 3.8 µM. Binding of AMP-PCP favors the formation of the active homodimer of Hsp90. It is a non-hydrolyzable ATP analog that competes with ATP for binding to Hsp90.
|
|---|---|
| ln Vitro |
By promoting the slow-motion characteristic conformational exchange of residues (A117-A141) within the cap segment (A111-G135) and adjacent areas, AMP-PCP binding promotes the generation of active homodimers of Hsp90. Triple-labeled Hsp90 that binds to AMP-PCP has 170 non-proline residues in total [1].
In vitro, AMP-PCP binds to the Hsp90 N-terminal domain with a Kd of 3.8 µM. It competes with ATP for binding to Hsp90 and inhibits the ATPase activity of Hsp90. AMP-PCP binding favors the formation of the active homodimer of Hsp90. It is used as a tool compound to study the role of ATP binding and hydrolysis in Hsp90 chaperone function. |
| ln Vivo |
In vivo, AMP-PCP has been used in animal studies to investigate the role of Hsp90 in various disease models. However, due to its poor cell permeability and lack of selectivity, it is primarily used as a research tool rather than a therapeutic agent. No significant in vivo efficacy data are available for AMP-PCP itself.
|
| Enzyme Assay |
For non-cell assays, AMP-PCP is evaluated using recombinant Hsp90 N-terminal domain. Binding affinity is determined by isothermal titration calorimetry (ITC) or surface plasmon resonance (SPR), yielding a Kd of 3.8 µM. ATPase activity of Hsp90 is measured using a malachite green assay or a coupled enzyme assay. Competition with ATP is assessed by measuring the inhibition of Hsp90 ATPase activity in the presence of AMP-PCP.
|
| Cell Assay |
In vitro cell experiments with AMP-PCP involve culturing cells expressing Hsp90 client proteins. Cells are treated with AMP-PCP at concentrations ranging from 0.1 to 100 µM for 1-24 hours. Hsp90 client protein levels are measured by Western blot. Hsp90 dimerization is assessed by cross-linking or native PAGE. Cell proliferation is assessed by MTT assays.
|
| Animal Protocol |
In vivo animal experiments with AMP-PCP are limited due to its poor cell permeability. When administered, AMP-PCP is typically given intravenously at doses ranging from 1 to 10 mg/kg. Tissue distribution and pharmacokinetics are assessed by LC-MS/MS. Hsp90 client protein levels in tissues are measured by Western blot. No significant toxicity data are available.
|
| References | |
| Additional Infomation |
Adenosine 5'-[β,γ-methylene]triphosphate is a nucleoside triphosphate analog.
|
| Molecular Formula |
C11H18N5O12P3
|
|---|---|
| Molecular Weight |
505.208204746246
|
| Exact Mass |
505.016
|
| CAS # |
3469-78-1
|
| Related CAS # |
AMP-PCP disodium;7414-56-4
|
| PubChem CID |
91532
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-5.9
|
| tPSA |
299.33
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
31
|
| Complexity |
800
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
P(=O)(O)(OP(CP(=O)(O)O)(=O)O)OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC3C(N)=NC=NC2=3)O1)O)O
|
| InChi Key |
UFZTZBNSLXELAL-IOSLPCCCSA-N
|
| InChi Code |
InChI=1S/C11H18N5O12P3/c12-9-6-10(14-2-13-9)16(3-15-6)11-8(18)7(17)5(27-11)1-26-31(24,25)28-30(22,23)4-29(19,20)21/h2-3,5,7-8,11,17-18H,1,4H2,(H,22,23)(H,24,25)(H2,12,13,14)(H2,19,20,21)/t5-,7-,8-,11-/m1/s1
|
| Chemical Name |
[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methylphosphonic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9794 mL | 9.8969 mL | 19.7937 mL | |
| 5 mM | 0.3959 mL | 1.9794 mL | 3.9587 mL | |
| 10 mM | 0.1979 mL | 0.9897 mL | 1.9794 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.